A Randomized, Multicenter, Open-Label Phase II Clinical Study Comparing the Efficacy and Safety of Zanubrutinib, Chidamide, and Rituximab Induction Therapy Sequentially Combined with or Without CHOP Versus R-CHOP in the First-Line Treatment of Patients with Newly Diagnosed Double-Expressor Diffuse Large B-cell Lymphoma
Latest Information Update: 29 Mar 2025
At a glance
- Drugs Rituximab (Primary) ; Tucidinostat (Primary) ; Zanubrutinib (Primary) ; Cyclophosphamide; Doxorubicin; Epirubicin; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 28 Mar 2025 New trial record